Genentech Sues Pfizer Over Herceptin Biosimilar Patents
Genentech filed a lawsuit aiming to stop Pfizer’s proposed Herceptin biosimilar from reaching the market — asking the court to compensate for losses in sales should the copy launch before…
EMA Adopts Guideline on Developing Treatments for Autism
The European Medicines Agency adopted a guideline for sponsors developing new products for autism spectrum disorder, providing recommendations on diagnostic criteria, target populations and clinical trial design. Source: Drug Industry…
FDA Outlines Guidance for Generic Abuse-Deterrent Opioid Pills
The FDA finalized guidance for manufacturers looking to produce generic versions of opioid painkillers with abuse-deterrent labeling, as a part of the agency’s push to lower overall exposure to opioids…
Meet the Under-the-Radar Biotech With a 'Novel' Alzheimer's Candidate
As the world watches big pharma companies take on the challenges of developing a viable therapy for ALZ’s disease, smaller companies are also attempting to blaze a treatment trail in…
Biogen Taps Biotech Vet as New CFO
Mr. Capello will lead Biogen’s Business Planning, Tax, Treasury, Internal Audit, Accounting, and Investor Relations functions. Source: BioSpace
Tiny Corbus Aims to Have Four Drugs in Mid- to Late-Stage Development by Next Year
In less than four years, Corbus has grown from a tiny startup to a public company with 60 employees and four assets in the clinic. Source: BioSpace
Palatin Forges $40.5M+ Deal With Korea's Kwangdong Pharma
Palatin has entered into a deal with Kwangdong, for exclusive rights to develop and commercialize bremelanotide for female sexual dysfunction indications in the Republic of Korea. Source: BioSpace
3 Biotechs That Have Investors Grinning at Thanksgiving Dinner This Year
Investors have had a decent year, but some have much to be grateful for this Thanksgiving. Source: BioSpace
Cytokinetics Scraps Lead ALS Drug After Late-Stage Trial Failure
Cytokinetics said it has suspended development of tirasemtiv after it failed to differentiate itself from placebo in a statistically significant manner. Source: BioSpace
Stanford, NCI Researchers Discover New CAR-T Target With Early Study Data
Instead of targeting a molecule called CD19 on the surface of the cancer cells, the new therapy targets a molecule called CD22. Source: BioSpace
- Go to the previous page
- 1
- …
- 249
- 250
- 251
- 252
- 253
- 254
- 255
- …
- 610
- Go to the next page